At a glance
ClinicalIndex Comparison RecordPhase 3Unknown· 654 enrolled
Drug / intervention
SHR3680 +1 moredrug
Likely dose
SHR3680 80 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase III, Multicenter, Randomized, Open Study of SHR3680 Compared to Bicalutamide in the Treatment of Patients With Hormone Sensitive Prostate Cancer
In Brief
A Phase 3 clinical trial evaluating SHR3680 and Bicalutamide for Prostate Cancer and Hormone-Dependent Prostate Cancer. Targeting 654 participants across 67 sites in 4 countries.
Detailed Summary
The aim of this study is to compare the safety and efficacy of SHR3680 with bicalutamide in the treatment of patients with hormone sensitive prostate cancer.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsProstate Cancer, Hormone-Dependent Prostate Cancer
CountriesBulgaria, China, Czechia, Poland
Collaborators--
Timeline
Phase 3UnknownOverdue
20192020202120222023202420252026
First PostedMay 2018
Enrollment StartMay 2018
Primary CompletionApr 2023
Study CompletionApr 2025
TodayJul 2026
First PostedMay 9, 2018
Enrollment StartMay 30, 2018
Primary CompletionApr 30, 2023
Study CompletionApr 30, 2025
TodayJul 1, 2026
Enrollment to primary: 4.9 yearsPosted 8.1 years ago
Interventions
SHR3680drug
Tablet. Specifications of 80 mg; orally, once a day
Bicalutamidedrug
Tablet. Specifications of 50 mg; orally, once a day